Regulatory Approval Retailing NSE: TRIMURTHI ·

Novelix Pharmaceuticals Promoters Acquire 3.37 Lakh Shares via Warrant Conversion

NSE Filing 4 min read 11 views
Novelix Pharmaceuticals Promoters Acquire 3.37 Lakh Shares via Warrant Conversion

Novelix Pharmaceuticals Ltd — Regulatory Approval · TRIMURTHI

Transaction Value

₹6.75 Cr

Warrant Conversion

Market Cap

₹122.25 Cr

Small Cap

Revenue TTM

₹132.31 Cr

Operating

PE TTM

47.82

Valuation

! Key Highlights

  • Acquisition of 3,37,500 equity shares via conversion of warrants
  • Total transaction value across promoter group entities totals ₹6.75 crore
  • Srinidhi Fine Chemicals LLP acquired the largest block of 2,10,000 shares
  • Post-allotment stake for Srinidhi Fine Chemicals LLP stands at 35.13 percent
  • Other participating promoters include Narhari Belide and Vupparapalli Chandrasekhar

Promoters of Novelix Pharmaceuticals have increased their equity stake by acquiring 3,37,500 shares through the conversion of warrants. The transaction, valued at ₹6.75 crore, was conducted on a preferential allotment basis across four promoter entities.

Warrant Conversion Details

Four entities from the promoter and promoter group exercised their right to convert warrants into equity shares of Novelix Pharmaceuticals. Srinidhi Fine Chemicals LLP led the transaction by acquiring shares worth 4.2 crore, while Narhari Belide, Vupparapalli Chandrasekhar, and Neha Gattu contributed the remaining amount. These allotments were executed on a preferential basis, following the earlier issuance of warrants.

The acquisition represents a significant commitment from the leadership group, consolidating their voting rights and equity interest in the pharmaceutical distribution and retail entity.

Business and Financial Context

Novelix Pharmaceuticals Limited, formerly known as Trimurthi Limited, operates primarily in the specialty retail and pharmaceutical sectors. The company reported an annual operating revenue of 132.31 crore for the previous fiscal year, marking a growth of over 330 percent year-on-year. While net profits reached 2.56 crore annually, the latest quarterly figures show a profit of 0.91 crore.

The stock maintains a momentum score of 61.75 on Trendlyne and has traded between a 52-week low of 38 and a high of 92.

Corporate Transformation

  • The company recently rebranded from Trimurthi Limited to Novelix Pharmaceuticals Limited to align with its core business focus
  • Headquartered in Hyderabad, the firm maintains a presence in the competitive pharmaceutical retail landscape of Telangana
  • Current promoter holding stands at 50.57 percent prior to the full impact of these recent warrant conversions
  • The firm carries a Piotroski Score of 5, indicating average financial strength and operational efficiency
  • Sector performance for retailing has seen a 100.99 percent growth in net profit year-on-year

Industry Landscape

The Indian specialty retail and pharmaceutical distribution market is experiencing a transition toward more organized structures. Mid-cap companies like Novelix are navigating a landscape shaped by increased regulatory oversight and the need for efficient supply chain management. The sector has seen robust revenue growth recently, with industry-wide net profit improvements.

Strategic stake increases by promoters often occur during periods of corporate restructuring or when leadership seeks to demonstrate long-term alignment with the company's growth trajectory and operational scaling.

Novelix Pharmaceuticals Ltd — Financial Snapshot

BSE: 536565 · NSE: TRIMURTHI · Retailing

Current Market Price ₹69.4 per share
Market Capitalisation ₹122.25 BSE Listed
Revenue (Annual) ₹132.31 Operating
Net Profit (Annual) ₹2.56 Consolidated
P/E Ratio (TTM) 47.82× Sector: 76×
Promoter Holding 50.57% -1.41% QoQ
FII Holding 0% Current Qtr

Source Verified

Exchange filing by Novelix Pharmaceuticals Limited announcing disclosure of share acquisition under Regulation 7(2) of SEBI PIT Regulations. Financial metrics from Trendlyne.

View Filing